Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Actelion shareholders back R&D spinoff, keep J&J deal on track

Published 05/04/2017, 12:05
Updated 05/04/2017, 12:10
© Reuters. The company's logo is seen at the headquarters of Swiss biotech company Actelion in Allschwil
ATLN
-
JNJ
-

ZURICH (Reuters) - Shareholders in Swiss biotech group Actelion (S:ATLN) approved on Wednesday spinning off its drug discovery and early clinical pipeline into a new company, keeping Johnson & Johnson's (N:JNJ) $30 billion (24.03 billion pounds) takeover on track to close in the second quarter.

"After a very successful two decades, resulting in an unprecedented share price increase of more than 2,000 percent since our IPO, the next chapter for Actelion awaits," Chairman Jean-Pierre Garnier said after the annual meeting.

"With the successful tender offer by Johnson & Johnson, regulatory approvals on track, and today's approval by the shareholders to spin out Idorsia, the transaction is moving ahead at full steam."

Johnson & Johnson last month declared its tender offer a success and reported it controlled 77.2 percent of Actelion's voting rights after the main offer period.

J&J intends to delist Actelion, while the new research and development company led by Actelion founder Jean-Paul Clozel will have a separate Swiss listing.

© Reuters. The company's logo is seen at the headquarters of Swiss biotech company Actelion in Allschwil

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.